SSRI Antidepressant Side Effects: Recognition and Management

14 min readUpdated 2 June 2026Medically reviewed

Disclosure: 247healthcare.blog publishes general health education reviewed by qualified doctors. Some articles contain affiliate links. This post does not. Our editorial process and medical review are independent of any commercial relationship. Full disclosure policy.

Emergency: serotonin syndrome

Some symptoms require immediate emergency care

Serotonin syndrome is a potentially life-threatening reaction usually occurring when SSRIs combine with other serotonergic medications. Seek immediate emergency care if any of the following occur:

High fever, sweating profusely, flushing
Rapid heart rate with elevated blood pressure
Severe agitation, confusion, or delirium
Muscle rigidity, tremor, twitching, or clonus
Dilated pupils
Severe diarrhoea or vomiting with above symptoms
Suspected after recent medication change, overdose, or combining medications

India: call emergency services 112 or go to nearest hospital emergency immediately. Tell medical staff about all medications and supplements taken.

If you need help right now

24-hour mental health crisis helplines

If you are in crisis or having thoughts of self-harm, please reach out.

Tele-MANAS (India): 14416 or 1800-891-4416, 24x7
KIRAN (India): 1800-599-0019, 24x7
Vandrevala Foundation: 1860-266-2345, 24x7
iCALL: 9152987821, Mon-Sat 8 AM to 10 PM
988 Lifeline (USA): 988, 24x7
Samaritans (UK): 116 123, 24x7

Key takeaways

SSRI side effects fall into three time categories: early effects (first 2 weeks, usually improving as body adjusts) including nausea, anxiety, headache, sleep disturbance; persistent effects continuing throughout treatment including sexual dysfunction (40-60 percent of patients); rare but serious effects requiring urgent attention including serotonin syndrome, hyponatremia, severe bleeding, and increased suicidal ideation in patients under 25 years (FDA black box warning).
Sexual dysfunction (reduced libido, delayed orgasm, erectile difficulties) affects 40-60 percent of SSRI patients and is the most common persistent side effect. Often under-reported because patients hesitate to discuss; clinically important because it affects quality of life and treatment adherence. Management options include dose adjustment, switching SSRIs, or switching to bupropion XL.
SSRIs differ substantially in side effect profiles. Sertraline and escitalopram generally well-tolerated; paroxetine has highest sexual side effects, most severe discontinuation syndrome, and anticholinergic effects making it less preferred particularly in elderly. Citalopram has QT prolongation risk at doses above 40 mg (20 mg in elderly). Fluoxetine has long half-life advantages but more drug interactions.
Discontinuation syndrome (FINISH: Flu-like, Insomnia, Nausea, Imbalance, Sensory disturbance, Hyperarousal) occurs when SSRIs are stopped suddenly. Gradual tapering under medical supervision substantially reduces risk. Short half-life SSRIs (paroxetine, fluvoxamine) produce more severe discontinuation symptoms than long half-life SSRIs (fluoxetine).
SSRIs are among the most studied and used psychiatric medications with substantial long-term safety data. Most patients tolerate SSRIs well over years when needed. Side effects should not be silently endured; discussion with prescribing doctor often leads to successful management through dose adjustment, switching, or augmentation strategies. Stopping SSRIs without medical guidance can produce discontinuation syndrome and depression relapse.

Medically reviewed by Dr. Boppana Sridhar (MBBS, MD Psychiatry, Australia-trained), Consultant Psychiatrist with 9+ years of clinical experience in antidepressant medication management including SSRI selection, side effect management, switching strategies, special populations (elderly, pregnancy, breastfeeding), and discontinuation. NMC-registered.

Last updated: 2 June 2026 | Last medically reviewed: 2 June 2026

SSRI antidepressants (Selective Serotonin Reuptake Inhibitors) are among the most prescribed psychiatric medications globally and the most commonly prescribed antidepressant class. Side effects affect a substantial proportion of patients and contribute to treatment discontinuation, dose limitations, and quality of life impact. Understanding side effects across three time categories (early effects in first 2 weeks usually improving, persistent effects continuing throughout treatment particularly sexual dysfunction, rare but serious effects requiring urgent attention) helps patients and families anticipate, recognise, and manage what occurs. This guide covers SSRI side effects comprehensively: mechanism explaining why they occur, common effects (gastrointestinal, sleep, sexual, weight, anxiety, headache, sweating), serious effects (serotonin syndrome, hyponatremia, bleeding, QT prolongation, FDA black box for under-25 patients), discontinuation syndrome including the FINISH mnemonic, SSRI-by-SSRI side effect comparison (sertraline, escitalopram, citalopram, fluoxetine, paroxetine, fluvoxamine), management strategies, considerations during pregnancy and breastfeeding, long-term safety, and India-specific access and cost context.

What SSRIs are

SSRIs (Selective Serotonin Reuptake Inhibitors) are a class of antidepressant medications that increase serotonin availability in the brain by blocking serotonin reuptake at neuronal synapses. They became the dominant antidepressant class from the late 1980s due to better side effect profiles than older antidepressants (tricyclic antidepressants and MAOIs).

SSRIs commonly prescribed in India and globally include:

Sertraline (brand names: Zoloft, Daxid, Sertima) - often first choice including during breastfeeding
Escitalopram (Lexapro, Cipralex, Nexito) - well-tolerated, fewer drug interactions
Citalopram (Cipramil, Celexa) - similar to escitalopram with QT prolongation concern at higher doses
Fluoxetine (Prozac, Flunil) - long half-life with discontinuation advantages
Paroxetine (Paxil, Pexep) - higher side effects, generally less preferred
Fluvoxamine (Luvox, Faverin) - less commonly used, more drug interactions

SSRIs are used not only for depression but for anxiety disorders, OCD, panic disorder, social anxiety, PTSD, eating disorders (some), and premenstrual dysphoric disorder. Side effect profiles are generally similar across indications.

SSRIs require prescription and medical supervision; they are not over-the-counter medications. See our MDD guide for depression context. Treatment decisions should be made with a qualified prescribing doctor; this guide provides general information about side effects to support informed discussion.

Why SSRIs cause side effects

SSRI side effects reflect the medication's serotonergic action affecting multiple body systems beyond the central nervous system target for mood improvement:

Brain effects. Serotonin receptors throughout the brain affect mood, anxiety, sleep, appetite, sexual function, and other systems. SSRI activity on these receptors produces both therapeutic mood improvement and side effects including sexual dysfunction, sleep changes, and anxiety alterations.

Gut effects. Approximately 90 percent of body serotonin is in the gut. SSRI effects on gut serotonin produce nausea, diarrhoea, and other GI symptoms common in early treatment.

Platelet effects. Platelets use serotonin in their function. SSRI effects on platelets contribute to bleeding risk particularly when combined with NSAIDs or anticoagulants.

Hormonal effects. Serotonin interacts with hormonal systems including those affecting sodium balance (contributing to hyponatremia risk) and other endocrine functions.

Sexual effects. Serotonin pathways affect arousal, lubrication, erection, and orgasm. SSRI effects on these pathways produce sexual dysfunction common across SSRI class.

Adaptation over time. Many side effects (GI, anxiety, sleep) improve as the body adjusts over 2-4 weeks. Other effects (sexual dysfunction particularly) often persist throughout treatment.

Side effects by time category

SSRI side effects fall into three time categories with different management implications:

Early effects (first 2 weeks)

Nausea, anxiety/jitteriness, headache, sleep disturbance, diarrhoea. Usually improve substantially as body adjusts over 1-2 weeks. Most patients should continue treatment through this period unless effects severe. Stopping in this period often loses opportunity for therapeutic mood benefit which takes 4-8 weeks.

Persistent effects (throughout treatment)

Sexual dysfunction (most common, 40-60 percent of patients), modest weight gain over months, sometimes continued sleep disturbance, sweating. These effects may require management through dose adjustment, switching SSRIs, or augmentation strategies. Should not be silently endured if affecting quality of life.

Rare but serious effects

Serotonin syndrome (drug combinations), hyponatremia (particularly elderly), severe bleeding (with NSAIDs/anticoagulants), QT prolongation (citalopram doses), suicidal ideation increase in under-25 patients (FDA black box). These require urgent attention regardless of treatment duration; recognition matters.

Understanding the time pattern helps patients and families anticipate what to expect. The first 2 weeks often involve substantial side effects that resolve; continuing through this period requires patience and prescribing doctor support. Persistent effects emerging later require active management discussion.

Early side effects (first 2 weeks)

Early SSRI side effects typically begin within days of starting and substantially improve over 1-2 weeks as the body adjusts.

Gastrointestinal effects

Nausea (15-30 percent of patients): most common early effect; usually improves in 1-2 weeks; taking medication with food reduces severity in many patients; persistent severe nausea warrants medication review. Diarrhoea (10-15 percent): often improves with continued treatment; sertraline tends to produce more diarrhoea than other SSRIs. Vomiting occasionally. Reduced appetite or increased appetite. Dry mouth particularly with paroxetine.

Anxiety and activation

Anxiety, jitteriness, restlessness, or activation in the first 1-2 weeks; paradoxically anxiety may worsen before improving. Sometimes substantial enough that benzodiazepines or other anti-anxiety medications are added briefly. Improves substantially over 1-2 weeks; if persistent, dose adjustment or SSRI change may be needed. Fluoxetine particularly produces activation; sertraline and escitalopram less activating.

Sleep effects

Insomnia (10-20 percent): difficulty falling asleep, fragmented sleep, vivid dreams. Sometimes hypersomnia particularly with paroxetine or fluvoxamine. Morning dosing (rather than evening) reduces insomnia for most SSRIs. Sleep effects may improve with continued treatment or require dose timing adjustment. Sleep hygiene measures help; melatonin sometimes added under medical guidance.

Headache

Headache common in first 1-2 weeks; usually mild to moderate; resolves as treatment continues. Persistent severe headache warrants assessment. Hydration and standard headache management (paracetamol) generally adequate; avoid NSAIDs particularly with elderly or anticoagulated patients due to bleeding interaction.

Sweating

Increased sweating including night sweats common with SSRIs; can be substantial. Sometimes persistent rather than improving. Hydration important. If severe and persistent, medication change may be considered. Sometimes confused with menopausal symptoms in women or thyroid issues; clinical context distinguishes.

The 2-week threshold. Most early side effects substantially improve by 2 weeks of treatment. Continuing through this period is important because therapeutic mood benefit typically requires 4-8 weeks; stopping early loses the opportunity for benefit. The exception is severe side effects requiring discontinuation; mild-to-moderate early effects typically warrant patience.

Persistent side effects

Some SSRI side effects continue throughout treatment rather than improving with adaptation:

Sexual dysfunction is the most common persistent SSRI side effect. Detailed coverage in next section.

Modest weight gain over months in many patients. Mechanisms include serotonergic effects on appetite, improved appetite as depression resolves, energy and metabolism changes. Average weight gain 2-4 kg over first year of treatment in many patients; substantial variation. Paroxetine associated with most weight gain; fluoxetine often weight-neutral or mild loss; sertraline and escitalopram moderate effects.

Continued sleep effects in some patients including insomnia, hypersomnia, vivid dreams, or fragmented sleep. May require sleep optimisation strategies or medication adjustment.

Sweating continues in some patients throughout treatment.

Emotional blunting. Some patients report reduced emotional range including reduced positive emotions; not formally recognised diagnostic side effect but reported in clinical practice and increasingly studied. May affect work performance, relationships, creativity. Discussion with prescribing doctor important; sometimes responds to dose adjustment or medication change.

Mild cognitive effects in some patients including subjective slowing, processing changes; usually mild and improving over time but persistent in some.

Persistent effects warrant management discussion with prescribing doctor. Options include dose adjustment, switching to different SSRI, switching to different antidepressant class, or augmentation strategies. The choice depends on therapeutic benefit obtained, side effect severity, and patient priorities.

Sexual dysfunction

40-60%

Sexual dysfunction affects 40-60 percent of patients on SSRIs. The most common persistent SSRI side effect; substantially under-reported because patients hesitate to discuss; clinically important for quality of life and treatment adherence.

SSRI sexual side effects include:

Reduced libido (decreased sexual interest or desire)
Delayed orgasm or anorgasmia (inability to reach orgasm)
Erectile difficulties in men
Vaginal dryness or reduced arousal in women
Reduced sexual sensation or genital numbness
Reduced ejaculatory volume in men

Both depression itself and SSRIs affect sexual function; distinguishing medication effect from underlying depression effect can be difficult. Sometimes treatment trial helps clarify. Patients sometimes have improved sexual function with SSRI treatment (as depression resolves) despite some medication-related effects.

Why this matters clinically. Sexual dysfunction substantially affects quality of life, relationship satisfaction, and treatment adherence. Many patients silently discontinue SSRIs due to sexual side effects without discussing alternatives with their prescribing doctor. Open discussion is essential.

Management options:

Discussion with prescribing doctor (essential first step)
Dose reduction if mood control allows (sometimes reduces sexual side effects)
Switching to SSRI with lower sexual side effects (escitalopram or sertraline often better tolerated than paroxetine)
Switching to bupropion XL (substantially fewer sexual side effects; sometimes weight loss; useful for both treatment and side effect management)
Switching to mirtazapine (fewer sexual effects; may cause weight gain and sedation)
Adding bupropion XL to current SSRI
For erectile difficulties, sildenafil or tadalafil under medical supervision
For women, consideration of other antidepressants or specific interventions
Brief drug holidays sometimes used (controversial, not for fluoxetine due to long half-life, requires careful planning, not appropriate for all patients)

Post-SSRI sexual dysfunction (PSSD). Rare reports of sexual side effects continuing after stopping SSRIs (genital numbness, anhedonia, persistent reduced libido). Research is ongoing; clinical recognition variable. Most patients fully recover sexual function after SSRI discontinuation, but rare prolonged cases are documented.

Serious side effects

Several SSRI side effects are uncommon but serious, requiring urgent attention regardless of treatment duration:

Serotonin syndrome (covered in detail next)
Hyponatremia/SIADH (low sodium, particularly elderly)
Severe bleeding (GI bleeding particularly with NSAIDs or anticoagulants)
QT prolongation (citalopram particularly at higher doses)
Suicidal ideation increase in patients under 25 years (FDA black box warning)
Severe allergic reactions (rare)
Hepatic effects (uncommon, requires monitoring in some patients)
Bone density effects (long-term, particularly elderly women)
Severe agitation, hostility, or behavioural changes (rare but recognised)
Mania or hypomania (particularly in patients with undiagnosed bipolar disorder)

The rare serious effects require pre-treatment risk assessment and ongoing monitoring. Most patients on SSRIs do not experience serious effects, but awareness allows early recognition when they occur.

Serotonin syndrome

Serotonin syndrome is a potentially life-threatening condition caused by excessive serotonergic activity. Most cases involve combinations of multiple serotonergic medications rather than SSRI monotherapy at standard doses.

Symptoms span three categories:

Neuromuscular abnormalities: tremor, hyperreflexia, clonus (rhythmic muscle contractions), muscle rigidity, ankle clonus (rhythmic foot movements when foot is dorsiflexed)
Autonomic instability: tachycardia (rapid heart rate), hypertension, hyperthermia (elevated body temperature, sometimes severe), sweating, dilated pupils, flushing, diarrhoea, shivering
Mental status changes: agitation, anxiety, confusion, restlessness; delirium in severe cases; in severe cases coma

Severity ranges from mild (tremor, restlessness, mild autonomic changes resolving with stopping medications) to severe (hyperthermia above 41°C, severe muscle rigidity, delirium, rhabdomyolysis with muscle breakdown, multi-organ failure, death).

Risk factors:

Combination of multiple serotonergic medications
SSRI with MAOI combination (particularly dangerous; requires washout periods when switching)
SSRI with tramadol (common pain medication; substantial risk)
SSRI with triptans (migraine medications; risk varies)
SSRI with fentanyl or other opioids
SSRI with linezolid (antibiotic)
SSRI with methylene blue (used in some surgeries)
SSRI with ondansetron (anti-nausea)
SSRI with St. John's Wort (herbal supplement)
SSRI with some recreational drugs (cocaine, MDMA/ecstasy, amphetamines)
Recent dose increase or overdose
Inadequate washout when switching antidepressants

Treatment of suspected serotonin syndrome: immediate emergency care; stop all serotonergic medications; supportive care including cooling for hyperthermia, sedation with benzodiazepines for agitation, IV fluids; in severe cases, cyproheptadine (serotonin antagonist); intensive care monitoring for severe cases.

Prevention. Clear communication with all prescribing doctors about all medications and supplements; awareness of dangerous combinations particularly tramadol and triptans; appropriate washout periods when switching antidepressants; caution when adding any new medication while on SSRI.

Hyponatremia (low sodium)

SSRIs can cause hyponatremia (low serum sodium) through Syndrome of Inappropriate Antidiuretic Hormone (SIADH). Risk is approximately 2-5 percent of SSRI patients overall but substantially higher in elderly patients (up to 25 percent in some studies of elderly SSRI users).

Symptoms of hyponatremia:

Confusion, lethargy
Fatigue, weakness
Headache
Nausea, sometimes vomiting
Falls (particularly elderly)
Severe cases: seizures, coma

Risk factors: elderly age (substantially increased risk); concurrent diuretics; low body weight; female gender (some studies); history of hyponatremia; recent SSRI initiation (first 2-4 weeks particularly).

Monitoring: sodium check 1-2 weeks after SSRI initiation in elderly patients is appropriate clinical practice; symptom-based monitoring otherwise; symptoms warrant urgent assessment particularly in elderly.

Management: mild hyponatremia may resolve with SSRI dose reduction or fluid restriction under medical guidance; moderate to severe hyponatremia requires medication discontinuation; severe symptomatic hyponatremia is medical emergency.

See our depression in elderly guide for detailed coverage of elderly antidepressant considerations.

Bleeding and QT prolongation

Bleeding risk. SSRIs affect platelet function and increase bleeding risk. The risk is substantially increased when SSRIs combine with:

NSAIDs (ibuprofen, naproxen, diclofenac) for GI bleeding
Aspirin even at low doses
Anticoagulants (warfarin, novel oral anticoagulants)
Antiplatelet medications (clopidogrel)
Combined with all of the above (substantial risk)

Most reported bleeding is GI bleeding; bleeding in other locations (skin, surgical sites, urinary, intracranial) also possible. Risk management includes: paracetamol instead of NSAIDs when possible; gastroprotection (PPI) when NSAIDs necessary alongside SSRI; close monitoring on anticoagulants; informing all doctors about SSRI use including before surgery (sometimes stopped before surgery, sometimes continued depending on indication).

QT prolongation. Citalopram in particular can prolong QT interval at higher doses; risk of arrhythmia (torsades de pointes) at very high doses or with QT-prolonging combinations. FDA recommends citalopram dose limit of 40 mg daily for most adults and 20 mg daily for elderly. Escitalopram has lower QT risk than citalopram. Other SSRIs have minimal QT effects at standard doses.

Patients with: pre-existing QT prolongation, congenital long QT syndrome, family history of sudden cardiac death, concurrent QT-prolonging medications (some antibiotics, antifungals, antipsychotics), or electrolyte abnormalities should have careful SSRI selection.

Black box warning under 25

The FDA black box warning (US) and equivalent warnings from other regulators (MHRA UK, others) state that SSRIs may increase suicidal thoughts and behaviour in children, adolescents, and young adults up to age 24. The risk is highest in the first weeks of treatment.

What the data shows. Meta-analyses of clinical trials in patients under 25 showed approximately 4 percent risk of suicidal thoughts or behaviour on SSRI vs 2 percent on placebo - relative increase but absolute risk modest. No completed suicides were reported in the trials. Risk appears highest in first 4 weeks.

Clinical implications. SSRIs are still appropriate for many young patients with moderate-to-severe depression where benefit outweighs risk. Untreated depression in young people carries its own substantial suicide risk; medication can reduce overall risk over treatment course.

Monitoring recommendations for patients under 25 on SSRIs:

Close monitoring particularly first 4 weeks of treatment
Weekly check-ins where possible during initiation
Family awareness of warning signs
Clear access plan if symptoms worsen
Direct discussion about emergence of suicidal thoughts
Asking about suicidal ideation does not increase risk (well-established research finding)

The warning should inform careful monitoring rather than avoiding SSRIs in young patients with substantial indication. Decision-making is individual; pre-treatment discussion of risks and monitoring plan is appropriate.

Discontinuation syndrome

Antidepressant discontinuation syndrome (sometimes called withdrawal syndrome) occurs when SSRIs are stopped suddenly or tapered too quickly after several weeks of treatment.

FINISH mnemonic for symptoms:

Flu-like symptoms: fatigue, body aches, sweating, chills, lethargy
Insomnia: sleep disturbance sometimes with vivid dreams or nightmares
Nausea: sometimes with vomiting or diarrhoea
Imbalance: dizziness, vertigo, ataxia, "rocking" sensation
Sensory disturbance: electric shock sensations ("brain zaps") particularly with head movement or eye movement, paraesthesia, blurred vision, tinnitus
Hyperarousal: anxiety, irritability, agitation, low mood, irritability, sometimes aggression

Time course. Symptoms typically begin within 1-3 days after stopping or substantial dose reduction; peak 4-7 days; resolve within 1-3 weeks in most patients. Some patients experience prolonged symptoms (weeks to months) requiring very gradual tapering or temporary reinstating medication.

Variation by SSRI:

Severe discontinuation: paroxetine (short half-life, severe symptoms), venlafaxine (SNRI, also severe), fluvoxamine
Moderate discontinuation: sertraline, citalopram, escitalopram
Mild discontinuation: fluoxetine (long half-life self-tapers; often used as bridge during tapering of other SSRIs)

Reducing discontinuation risk:

Gradual tapering over weeks to months under prescribing doctor supervision
Longer treatment duration generally requires slower tapering
Some patients require very slow tapering (10 percent dose reduction every few weeks)
Fluoxetine sometimes used as bridge during tapering of shorter half-life SSRIs
Plan tapering during stable life period when possible
Avoid stopping abruptly even when feeling well

Distinguishing discontinuation from depression relapse:

Discontinuation symptoms include physical features (brain zaps, flu-like, dizziness) less typical of depression
Discontinuation starts quickly (1-3 days) vs depression relapse usually slower (weeks)
Discontinuation symptoms improve with restarting medication within days vs depression relapse requires weeks of treatment
Both can coexist; sometimes depression relapses during tapering

SSRI-by-SSRI comparison

SSRI	Common considerations	Side effect profile notes
Sertraline	Often first choice; well-tolerated; breastfeeding-compatible (first-line); low drug interactions	More GI effects (diarrhoea); moderate sexual side effects; modest weight gain; moderate discontinuation
Escitalopram	Well-tolerated; clean side effect profile; lower drug interactions than fluoxetine/fluvoxamine	Modest sexual side effects (less than paroxetine); modest weight gain; moderate discontinuation; lower QT than citalopram
Citalopram	Similar to escitalopram with QT concern; dose limits apply (40 mg adults, 20 mg elderly)	Modest sexual side effects; modest weight gain; moderate discontinuation; QT prolongation at higher doses
Fluoxetine	Long half-life (5-7 days; metabolite weeks); milder discontinuation; useful for poor adherence	More activation/anxiety initially; significant drug interactions (CYP2D6/2C19); modest sexual effects; weight-neutral or initial loss
Paroxetine	Generally less preferred; high anticholinergic burden; severe discontinuation; avoided in elderly when possible	Highest sexual side effects; most weight gain; severe discontinuation; sedation; anticholinergic effects (dry mouth, constipation); avoid in pregnancy when alternatives
Fluvoxamine	Less commonly used; significant CYP1A2 interactions; primarily OCD indication	More GI effects; more sedation; significant drug interactions; severe discontinuation

First-line choices. Sertraline and escitalopram are often first-line SSRIs given balanced side effect profiles, manageable discontinuation, lower drug interactions, and good evidence base. Individual variation matters substantially; some patients tolerate one SSRI well and another poorly.

Switching between SSRIs is common when side effects are problematic or response inadequate. Switching strategy varies by medications involved; direct switch with no gap, cross-titration, or washout strategies depending on circumstances. Should be done under prescribing doctor supervision.

Managing side effects

SSRI side effect management follows a stepwise approach:

Step 1: Time. Many early side effects (GI, anxiety, headache, sleep) improve within 2-4 weeks of continued treatment. Patience and supportive measures (food with medication, hydration, sleep timing) often allow continuation through this period.

Step 2: Dose adjustment. Sometimes side effects respond to dose reduction while maintaining therapeutic benefit. Sometimes dose increase paradoxically improves tolerance through receptor adaptation. Should be done with prescribing doctor.

Step 3: Dose timing. Morning dosing reduces insomnia for most SSRIs; evening dosing helps if sedation is the effect; with food reduces GI effects.

Step 4: Switching SSRIs. Different SSRIs have different side effect profiles; switching to better-tolerated SSRI common when first choice problematic.

Step 5: Switching to different antidepressant class. Bupropion XL (different mechanism, fewer sexual effects, sometimes weight loss); mirtazapine (different mechanism, fewer sexual effects, may cause weight gain and sedation); SNRIs (similar serotonergic effects but different profile in some patients).

Step 6: Augmentation strategies. Adding bupropion XL to current SSRI for sexual dysfunction or to enhance response. Other combinations under specialist guidance.

Step 7: Specific symptom management. Sildenafil for SSRI-related erectile dysfunction; melatonin for sleep effects; cyproheptadine sometimes for sexual dysfunction (controversial); paracetamol for headache (avoid NSAIDs when possible).

The choice between these steps depends on therapeutic benefit obtained, side effect severity and type, patient preference, and clinical context. Active discussion with prescribing doctor is essential rather than silent discontinuation.

Pregnancy and breastfeeding

SSRI use during pregnancy and breastfeeding requires balancing maternal mental health benefits against fetal/infant exposure considerations.

Pregnancy considerations:

Most SSRIs considered relatively safe during pregnancy; risks generally low
Paroxetine generally avoided due to slightly higher rates of fetal cardiac malformations
Sertraline often first choice during pregnancy
Untreated maternal depression carries substantial risks to both mother and fetus
Neonatal adaptation syndrome (transient withdrawal-like symptoms in newborn) can occur
Persistent pulmonary hypertension of the newborn (PPHN) rare risk with late pregnancy SSRI
Decision should be made with prescribing doctor and obstetrician considering individual risks and benefits

Breastfeeding considerations:

Most SSRIs compatible with breastfeeding with minimal infant exposure
Sertraline often first choice during breastfeeding (low milk transfer, well-studied)
Escitalopram also commonly used
Fluoxetine has somewhat higher infant exposure due to long half-life but generally considered compatible
Monitoring of infant for changes in feeding, sleep, weight gain
Untreated maternal depression carries substantial risks

See our postpartum depression guide for detailed coverage of perinatal mental health and treatment considerations.

Long-term considerations

SSRIs are among the most studied psychiatric medications with substantial long-term safety data.

Long-term safety considerations:

Most patients tolerate SSRIs safely for years when needed
Persistent side effects (particularly sexual dysfunction) continue throughout treatment
Bone density: some research suggests SSRI use associated with reduced bone mineral density and increased fracture risk particularly in elderly women; clinical significance varies
Cardiovascular: long-term SSRI use generally cardiovascular-neutral or possibly cardioprotective due to depression-cardiovascular relationship
Bleeding risk continues throughout treatment
Hyponatremia risk continues, particularly elderly
Mild weight gain may continue gradually over years in some patients
Cognitive effects: long-term SSRI use generally cognitive-neutral; some patients report emotional blunting
Rare post-SSRI sexual dysfunction (PSSD) where sexual side effects continue after stopping

Treatment duration recommendations:

First episode: typically 6-12 months minimum after acute response
Recurrent episodes (2 or more): typically 2 years or longer
Multiple recurrences (3 or more): often indefinite maintenance treatment
Specific patient factors affecting duration: severity, recurrence pattern, response, side effect tolerance

Periodic review during long-term treatment: need for continued treatment, mood assessment, side effect monitoring, specific monitoring depending on individual factors (sodium for elderly, bone health for older women, blood pressure, lipids periodically).

India context

SSRI use in India has specific access and prescribing patterns:

Availability. All commonly used SSRIs (sertraline, escitalopram, citalopram, fluoxetine, paroxetine, fluvoxamine) are widely available in India. Both branded and generic versions available; generic equivalents substantially less expensive than branded.

Cost considerations. SSRI costs in India are substantially lower than in many other countries due to generic manufacturing. Typical monthly cost range for generic SSRIs in India: 150-1,000 INR depending on medication, dose, and source. Branded versions higher. Cost affordability is generally better than for many other classes of medication; however, sustained treatment costs accumulate.

Generic availability. Indian generic pharmaceutical industry produces all major SSRIs at substantially lower cost than branded versions. Quality variation exists; established generic manufacturers generally reliable.

Prescription requirements. SSRIs require prescription in India under Schedule H of Drugs and Cosmetics Act. Should not be self-medicated. Prescribing typically by general practitioner, psychiatrist, or other qualified doctor.

Indian prescribing patterns. Sertraline and escitalopram most commonly prescribed first-line; fluoxetine common particularly for younger patients or where adherence concerns; paroxetine still prescribed though less than ideal as first-line; fluvoxamine occasionally for OCD particularly.

Indian psychiatric services. NIMHANS Bengaluru, AIIMS Delhi, government district mental health programmes, and private psychiatric services provide SSRI prescription and monitoring. Tele-MANAS (14416) provides 24x7 guidance. Rural access remains limited.

Cultural considerations. Sexual side effects may be particularly under-reported in Indian context due to cultural sensitivities; explicit asking by prescribing doctor important. Discontinuation without medical guidance is concerning pattern; medication continuity messaging important.

Polypharmacy. Indian elderly often on multiple medications; drug interaction assessment important when adding SSRI. Self-medication with NSAIDs (commonly available OTC) creates bleeding interaction risk; awareness important.

When to contact doctor

Routine contact with prescribing doctor is appropriate for:

Side effects affecting quality of life
Side effects persisting beyond 2-4 weeks
Questions about medication changes
Pregnancy planning or pregnancy diagnosis
Planned discontinuation
Inadequate mood response after 4-8 weeks at therapeutic dose
Routine follow-up monitoring

Urgent contact (same day) is appropriate for:

Suspected serotonin syndrome symptoms (fever, agitation, muscle rigidity, tremor)
Symptoms suggesting hyponatremia (confusion, severe fatigue, falls in elderly)
Signs of bleeding (black stools, blood in vomit, unusual bruising, severe bleeding)
Severe side effects affecting safety
Worsening depression or new onset of suicidal thoughts
New manic or hypomanic symptoms (high mood, racing thoughts, decreased sleep, grandiose thinking, impulsive behaviour)
Suspected adverse drug interaction
Severe allergic reaction (rash, swelling, breathing difficulty)
Severe discontinuation symptoms if attempting to stop
Cardiac symptoms (palpitations, syncope) particularly on citalopram or QT-affecting combinations
Pregnancy diagnosed while on SSRI
Self-harm or suicide thoughts increasing

In India, contact prescribing doctor or psychiatric services; for emergencies, Tele-MANAS 14416 or 112 emergency services; for severe symptoms, nearest hospital emergency.

A note from Dr. Boppana Sridhar

SSRI side effects are one of the most common reasons patients silently discontinue antidepressant treatment, often without telling their prescribing doctor. This silent discontinuation pattern is unfortunate because most side effect problems are manageable with active discussion. Early effects (nausea, anxiety, sleep disturbance) usually improve within 2 weeks; patience and supportive measures often allow continuation through this period. Sexual dysfunction is the most common reason patients want to stop SSRIs; this should not be silently endured. The good news is that there are many management options: dose adjustment, switching to a different SSRI with better sexual profile, switching to bupropion XL (substantially fewer sexual effects), or augmentation strategies. What I want to emphasise: SSRIs work very well for many patients with depression and anxiety; depression itself is more harmful than the medication side effects for most patients; if side effects are problematic, the answer is discussion and management, not silent discontinuation. For Indian patients particularly, sexual side effects may not be discussed due to cultural sensitivities; please raise these directly with your doctor even if uncomfortable, because management options exist. Stopping SSRIs requires gradual tapering over weeks to months; sudden discontinuation causes the FINISH symptoms (Flu-like, Insomnia, Nausea, Imbalance, Sensory, Hyperarousal) which patients sometimes mistake for depression relapse. Patient education and family awareness substantially improve outcomes; this is one reason resources like this guide matter.

Frequently asked questions

What are the most common SSRI side effects?

The most common SSRI side effects affect multiple body systems. Gastrointestinal effects are most common in early treatment: nausea (15-30 percent of patients), diarrhoea (10-15 percent), occasionally vomiting, reduced or increased appetite, dry mouth. Most GI effects improve within 1-2 weeks of starting or after dose adjustment. Sleep changes are common: insomnia (10-20 percent), sometimes hypersomnia, vivid dreams, restless sleep. Sleep effects may persist longer than GI effects. Sexual dysfunction is very common but often under-reported: reduced libido, delayed orgasm, anorgasmia, erectile difficulties affecting 40-60 percent of patients. Sexual effects often persist throughout treatment unlike other side effects. Weight changes occur: mild weight loss initially in some patients, modest weight gain over months in many patients. Anxiety, jitteriness, or restlessness may worsen in first 1-2 weeks before improvement. Headache common in early treatment, usually resolves. Sweating (often night sweats), sometimes substantial. Most SSRI side effects are mild and improve over 2-4 weeks of continued treatment; sexual dysfunction is the notable exception that often persists. Discussion with prescribing doctor is important for any side effect substantially affecting quality of life; switching to different SSRI or different class often manages side effect problems.

How long do SSRI side effects last?

SSRI side effects have different time courses that matter for treatment decisions. Early side effects (first 2 weeks): nausea, diarrhoea, anxiety/jitteriness, headache, sleep disturbance commonly occur in the first 1-2 weeks and substantially improve as the body adjusts. Most patients should continue treatment through this period because effects typically resolve. Persistent side effects (continue throughout treatment): sexual dysfunction is the most common persistent effect; some patients experience continued sleep disturbance, sweating, mild weight changes. Persistent effects may require dose adjustment, switching to different SSRI, addition of another medication to counteract specific effects, or accepting trade-off if mood benefit substantial. Rare but serious effects (require urgent attention regardless of timing): serotonin syndrome, hyponatremia, severe bleeding, suicidal ideation increase particularly in patients under 25 years. Discontinuation effects (when stopping): if stopped suddenly after several weeks of treatment, discontinuation syndrome (FINISH symptoms: Flu-like, Insomnia, Nausea, Imbalance, Sensory disturbance, Hyperarousal) can occur lasting days to weeks. Gradual tapering reduces discontinuation risk. Time pattern: most early effects improve in 2-4 weeks; therapeutic mood benefit also takes 4-8 weeks. Patients sometimes stop SSRIs in the first 2 weeks before therapeutic benefit, due to early side effects; discussing this pattern in advance and continuing through initial period (unless severe effects) is important.

Do SSRIs cause sexual dysfunction?

Yes, SSRIs commonly cause sexual dysfunction; this is one of the most common and frequently under-discussed SSRI effects. Approximately 40-60 percent of patients on SSRIs experience some form of sexual dysfunction; rates vary by SSRI, dose, and individual patient. Common SSRI sexual effects include: reduced libido (decreased sexual interest); delayed orgasm or anorgasmia (inability to reach orgasm); erectile difficulties in men; vaginal dryness or reduced arousal in women; reduced sexual sensation. Both depression itself and SSRIs affect sexual function; distinguishing medication effect from depression effect can be difficult and may require treatment trial. Management options for SSRI-induced sexual dysfunction include: discussing with prescribing doctor (essential first step); dose reduction if mood control allows; switching to SSRI with lower sexual side effects (escitalopram or sertraline often better tolerated than paroxetine); switching to bupropion XL (substantially fewer sexual effects); switching to mirtazapine (fewer sexual effects); adding bupropion XL to current SSRI; for some patients, sildenafil or tadalafil for erectile difficulties under medical supervision; brief drug holidays sometimes used (controversial, not for fluoxetine, requires careful planning). Sexual side effects should not be silently endured; quality of life impact warrants management discussion with prescribing doctor. Some patients prioritise mood benefit over sexual function temporarily; others find sexual function preservation worth medication adjustment. Both choices are legitimate.

Can you stop SSRIs suddenly? What is discontinuation syndrome?

SSRIs should not be stopped suddenly; abrupt cessation can cause antidepressant discontinuation syndrome (sometimes called withdrawal syndrome). Discontinuation syndrome characteristics: typically begins within 1-3 days after stopping or substantial dose reduction; symptoms peak 4-7 days and resolve within 1-3 weeks in most patients; some patients experience prolonged symptoms requiring slower tapering or temporary reinstating medication. Symptoms (FINISH mnemonic): Flu-like symptoms (fatigue, body aches, sweating, chills); Insomnia (sometimes with vivid dreams or nightmares); Nausea (sometimes with vomiting, diarrhoea); Imbalance (dizziness, vertigo, ataxia); Sensory disturbance (electric shock sensations called 'brain zaps' particularly with head movement, paraesthesia, blurred vision); Hyperarousal (anxiety, irritability, agitation, low mood, irritability). Severity varies by medication, duration of treatment, and individual factors. SSRIs with short half-lives (paroxetine, fluvoxamine) produce more severe discontinuation symptoms; longer half-life SSRIs (fluoxetine particularly) produce milder symptoms. Reducing risk: gradual tapering over weeks to months under doctor supervision; longer treatment duration may require slower tapering; fluoxetine sometimes used as bridge during tapering of other SSRIs (longer half-life self-tapers); plan tapering during stable life period when possible. Discontinuation syndrome is different from depression relapse: discontinuation symptoms include physical features (brain zaps, flu-like, dizziness) less typical of depression; symptoms start quickly after stopping vs depression relapse usually slower; symptoms improve with restarting medication within days vs depression relapse requires weeks of treatment. Discussing tapering plan with prescribing doctor before stopping is essential.

Are SSRIs safe long-term?

SSRIs are among the most studied and used psychiatric medications with substantial long-term safety data. Most patients can take SSRIs safely for years when needed. Long-term considerations include: persistent side effects (particularly sexual dysfunction) continue throughout treatment in patients affected; bone density: some research suggests SSRI use associated with reduced bone mineral density and increased fracture risk particularly in elderly; clinical significance varies; serotonin syndrome risk continues throughout treatment; hyponatremia risk continues, particularly elderly; bleeding risk (GI bleeding particularly when combined with NSAIDs or anticoagulants) continues; QT prolongation with citalopram doses above 40 mg (20 mg in elderly) requires monitoring; weight gain may continue gradually over years in some patients; sexual side effects persist; rare reports of post-SSRI sexual dysfunction (PSSD) where sexual side effects continue after stopping (research ongoing); rare reports of persistent symptoms after stopping including emotional blunting in some patients. Monitoring during long-term treatment: periodic review of need for continued treatment; mood assessment; side effect monitoring; specific monitoring depending on individual factors (sodium for elderly, bone health for older women, blood pressure, lipids periodically). Treatment duration: typically 6-12 months minimum after acute response for first episode; longer for recurrent episodes (5+ years or indefinite for some patients with multiple recurrences). Most psychiatric guidelines support long-term SSRI use when needed for prevention of recurrence. The risk-benefit calculation involves balancing continued depression risk (substantial morbidity, mortality, and suicide risk) against medication side effect burden. Most patients tolerate long-term SSRIs well with manageable side effects.

Which SSRI has the fewest side effects?

Side effect profiles vary across SSRIs, with several considered generally well-tolerated. Comparison considerations vary by patient and depend on individual response, comorbidities, and specific concerns. Sertraline (Zoloft) is often considered well-tolerated overall: low drug interactions, well-studied in breastfeeding (often first choice during breastfeeding), reasonable sexual side effect profile (less severe than paroxetine), GI effects common but improve. Escitalopram (Lexapro, Cipralex) is often well-tolerated: cleaner side effect profile than older SSRIs, fewer drug interactions, lower sexual side effects than some SSRIs, lower QT prolongation risk than citalopram. Citalopram (Cipramil) similar to escitalopram but QT prolongation concern at doses above 40 mg (20 mg in elderly); recommended dose limits apply. Fluoxetine (Prozac) has long half-life advantages: milder discontinuation syndrome, useful in patients with adherence concerns. Side effects: anxiety/activation common initially, drug interactions concerns, longer time for switching medications. Paroxetine (Paxil, Pexep) is least preferred for most patients: highest sexual side effect rates, most severe discontinuation syndrome, anticholinergic effects (problematic in elderly), weight gain more common, drug interactions. Generally avoided in elderly and when alternatives available. Fluvoxamine (Luvox, Faverin) is less commonly used: CYP1A2 drug interactions significant, GI effects common, sedation more common. Individual variation matters substantially; some patients tolerate one SSRI poorly but another well. Side effect-driven switching is common in clinical practice. Sertraline and escitalopram are often first choice given side effect profiles.

What is serotonin syndrome and how serious is it?

Serotonin syndrome is a potentially serious condition caused by excessive serotonergic activity, typically from drug combinations or overdose; can be life-threatening in severe cases. Serotonin syndrome can occur with SSRI alone but is uncommon at standard doses; risk substantially increases when SSRI is combined with other serotonergic medications. Symptoms span three categories: neuromuscular abnormalities (tremor, hyperreflexia, clonus, muscle rigidity, ankle clonus); autonomic instability (tachycardia, hypertension, hyperthermia/elevated temperature, sweating, dilated pupils, flushing, diarrhoea); mental status changes (agitation, anxiety, confusion, delirium in severe cases). Severity ranges from mild (tremor, restlessness, mild autonomic changes) to severe (hyperthermia, severe rigidity, delirium, rhabdomyolysis, multi-organ failure, death). Risk factors for serotonin syndrome: combination of multiple serotonergic medications (SSRIs with MAOIs is particularly dangerous; SSRIs with tramadol, fentanyl, ondansetron, triptans, linezolid, methylene blue); recent overdose or accidental excessive dosing; switching between antidepressants without appropriate washout period; combination with St. John's Wort or other herbal serotonergic supplements; some recreational drugs (cocaine, ecstasy, amphetamines). Mild serotonin syndrome resolves within 24-72 hours of stopping serotonergic medications. Severe cases require emergency hospitalisation with supportive care, cooling, sedation, and sometimes cyproheptadine (serotonin antagonist). Prevention: clear communication with all doctors about all medications and supplements; appropriate washout periods when switching; awareness of dangerous combinations particularly tramadol and triptans. If suspected, urgent medical assessment is required. Most serotonin syndrome cases are mild and resolve with discontinuation of offending medications.

Can SSRIs cause weight gain?

Yes, SSRIs can cause weight gain, though the effect varies substantially by medication and individual patient. Weight effect pattern with SSRIs: early treatment (first weeks): some patients experience mild weight loss due to nausea, reduced appetite, or improved mood reducing emotional eating; medium-term (months to year): modest weight gain common (typical 2-4 kg over first year); long-term (years): continued modest gain in some patients. Mechanisms proposed include: appetite changes related to serotonin signalling; improved appetite as depression resolves; energy and metabolism changes; possibly serotonin effects on satiety signalling. Variation by SSRI: paroxetine associated with most weight gain; fluoxetine often weight-neutral or mild loss particularly initially; sertraline modest weight gain in many patients; escitalopram modest weight gain in many patients; mirtazapine (not strictly SSRI but related) substantial weight gain common. Individual variation substantial; some patients lose weight, some remain stable, some gain. Genetic factors may explain some variation. Management of SSRI-related weight gain: discussion with prescribing doctor; assessment of whether weight change relates to medication or recovered appetite from depression resolution; lifestyle measures (diet, physical activity); switching to weight-neutral antidepressant (bupropion XL associated with weight loss in some patients); accepting modest weight gain if mood benefit substantial. The weight gain should be weighed against substantial mood benefit; the depression itself can affect weight, eating patterns, and metabolic health. Patients with strong concerns about weight should discuss alternatives such as bupropion XL with their prescribing doctor.

Medical disclaimer: This article provides general health education and does not replace personalised consultation with a qualified prescribing doctor. SSRI prescription, dose decisions, switching, and discontinuation should be managed by a qualified prescribing doctor. Do not start, stop, or change SSRI medications without medical guidance. If you suspect serotonin syndrome, severe hyponatremia, or other serious side effects, seek immediate emergency care. If you are experiencing severe symptoms or thoughts of self-harm, contact a crisis helpline or emergency services immediately.

About the author

247healthcare.blog editorial team writes general health and preventive medicine content reviewed by qualified doctors. Every article is fact-checked against current guidance from DSM-5, ICD-10/11, NICE NG222, APA, WHO, FDA, MHRA, Cochrane reviews, and peer-reviewed antidepressant pharmacology literature before publication.

About the medical reviewer

Dr. Boppana Sridhar (MBBS, MD Psychiatry, Australia-trained) is the Consultant Psychiatrist and department lead for Psychiatry and Psychology at Vivekananda Hospital, Begumpet, Hyderabad. He has 9+ years of clinical experience in antidepressant medication management including SSRI selection, side effect management, switching strategies, special populations (elderly, pregnancy, breastfeeding), and discontinuation. NMC-registered.